Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,totalCurrentAssets,netReceivables,accountsPayable,propertyPlantEquipment,shortTermInvestments,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,ENDV,-19219861.0,60459800,,,-1296669,,-1296669,599837,29784,-570053,-570053,,-120198,,,,0,30284,600337,500,-726616,,-1296669,-1296669,2235812.0,40327526.0,19258515.0,-16984049.0,5903803.0,2274492.0,6067.0,-57316072.0,79825.0,-1570.0,8538.0,19178690.0,6538340.0,-1570.0,38680.0,9417.0,711235.0,,,-10604.0,58500.0,58500.0,347592.0,-77434.0,-135934.0,161728.0,-1940.0,633208.0,,-19140010.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,0.032,1630507596,0.010000002,0.022,0.03219,0.022,1262746,ENDONOVO THERAPEUTICS INC,PNK,REGULAR,-0.082846984,0,False,False,45.45455,0.022 - 0.03219,0.022,0.0,0.0,0,0,finmb_182706281,Other OTC,"Endonovo Therapeutics, Inc.",USD,146548,149583,0.017900001,1.2695036,0.0141 - 0.125,-0.092999995,-0.74399996,0.0141,0.125,1576800000,1588622400,1588622400,1588622400,-0.339,4,-0.31,0.027566666,0.0044333357,0.16082235,0.03489058,-0.0028905794,1934713,-0.10322581,15,America/New_York,EDT,-14400000,1.58,,,0.125,0.0141,0.0276,0.0349,146.55k,149.58k,60.46M,,65.73M,0.05%,0.00%,,,,,,,,,,,0.00%,"Dec 19, 2019",,1:1000,"Dec 19, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,"-2,396.36%",-67.48%,,116.48k,0.00,-32.10%,100.43k,-2.14M,-7.08M,-0.3390,,8.54k,0,6.66M,,0.00,-0.31,-715.41k,2.47M,Value,91367,Healthcare,"Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its electrocuetical medical devices are also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post- concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.",Woodland Hills,800 489 4774,CA,1609372800,United States,http://www.endonovo.com,86400,6320 Canoga Avenue,818 230 9899,Biotechnology,15th Floor
t-1,ENDV,-18370682.0,60459800,,,-2680881,,-2680881,622638,32194,-590444,-590444,,-347402,,,,0,34715,625159,2521,-2090437,,-2680881,-2680881,2397540.0,40042679.0,18494829.0,-15973142.0,5289597.0,2521713.0,5152.0,-56019403.0,155000.0,-1570.0,85972.0,18339829.0,6598509.0,-1570.0,124173.0,7477.0,721840.0,,,20908.0,236500.0,362500.0,380576.0,72552.0,-289948.0,163308.0,-6535.0,1790676.0,126000.0,-18215656.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,0.032,1630507596,0.010000002,0.022,0.03219,0.022,1262746,ENDONOVO THERAPEUTICS INC,PNK,REGULAR,-0.082846984,0,False,False,45.45455,0.022 - 0.03219,0.022,0.0,0.0,0,0,finmb_182706281,Other OTC,"Endonovo Therapeutics, Inc.",USD,146548,149583,0.017900001,1.2695036,0.0141 - 0.125,-0.092999995,-0.74399996,0.0141,0.125,1576800000,1588622400,1588622400,1588622400,-0.339,4,-0.31,0.027566666,0.0044333357,0.16082235,0.03489058,-0.0028905794,1934713,-0.10322581,15,America/New_York,EDT,-14400000,1.58,,,0.125,0.0141,0.0276,0.0349,146.55k,149.58k,60.46M,,65.73M,0.05%,0.00%,,,,,,,,,,,0.00%,"Dec 19, 2019",,1:1000,"Dec 19, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,"-2,396.36%",-67.48%,,116.48k,0.00,-32.10%,100.43k,-2.14M,-7.08M,-0.3390,,8.54k,0,6.66M,,0.00,-0.31,-715.41k,2.47M,Value,91367,Healthcare,"Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its electrocuetical medical devices are also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post- concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.",Woodland Hills,800 489 4774,CA,1609372800,United States,http://www.endonovo.com,86400,6320 Canoga Avenue,818 230 9899,Biotechnology,15th Floor
t-2,ENDV,-16933080.0,60459800,,,-2030310,,-2030310,-2835,-35549,-683961,-683961,,-552699,,,,0,11500,695461,47049,-1346349,,-2030310,-2030310,2559268.0,38963827.0,16980821.0,-14373812.0,4202597.0,2607035.0,2453.0,-53338522.0,155000.0,-1570.0,13420.0,16825821.0,6491039.0,-1570.0,46187.0,942.0,700932.0,1580.0,,12196.0,203693.0,203693.0,273012.0,10837.0,-192856.0,162631.0,-6535.0,1214792.0,126000.0,-16779634.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,0.032,1630507596,0.010000002,0.022,0.03219,0.022,1262746,ENDONOVO THERAPEUTICS INC,PNK,REGULAR,-0.082846984,0,False,False,45.45455,0.022 - 0.03219,0.022,0.0,0.0,0,0,finmb_182706281,Other OTC,"Endonovo Therapeutics, Inc.",USD,146548,149583,0.017900001,1.2695036,0.0141 - 0.125,-0.092999995,-0.74399996,0.0141,0.125,1576800000,1588622400,1588622400,1588622400,-0.339,4,-0.31,0.027566666,0.0044333357,0.16082235,0.03489058,-0.0028905794,1934713,-0.10322581,15,America/New_York,EDT,-14400000,1.58,,,0.125,0.0141,0.0276,0.0349,146.55k,149.58k,60.46M,,65.73M,0.05%,0.00%,,,,,,,,,,,0.00%,"Dec 19, 2019",,1:1000,"Dec 19, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,"-2,396.36%",-67.48%,,116.48k,0.00,-32.10%,100.43k,-2.14M,-7.08M,-0.3390,,8.54k,0,6.66M,,0.00,-0.31,-715.41k,2.47M,Value,91367,Healthcare,"Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its electrocuetical medical devices are also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post- concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.",Woodland Hills,800 489 4774,CA,1609372800,United States,http://www.endonovo.com,86400,6320 Canoga Avenue,818 230 9899,Biotechnology,15th Floor
t-3,ENDV,-15483304.0,60459800,,,-1069041,,-1069041,986019,39220,-946799,-946799,,-432108,,,,0,39980,986779,760,-122242,,-1069041,-1069041,2720996.0,38545743.0,15494386.0,-12762308.0,3456851.0,2732104.0,1731.0,-51308212.0,155000.0,-1570.0,2583.0,15339386.0,5955373.0,-1570.0,8625.0,942.0,762175.0,2483.0,2500.0,72070.0,-6000.0,94000.0,585895.0,-2673.0,-96673.0,162631.0,-1.0,138268.0,100000.0,-15330761.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,0.032,1630507596,0.010000002,0.022,0.03219,0.022,1262746,ENDONOVO THERAPEUTICS INC,PNK,REGULAR,-0.082846984,0,False,False,45.45455,0.022 - 0.03219,0.022,0.0,0.0,0,0,finmb_182706281,Other OTC,"Endonovo Therapeutics, Inc.",USD,146548,149583,0.017900001,1.2695036,0.0141 - 0.125,-0.092999995,-0.74399996,0.0141,0.125,1576800000,1588622400,1588622400,1588622400,-0.339,4,-0.31,0.027566666,0.0044333357,0.16082235,0.03489058,-0.0028905794,1934713,-0.10322581,15,America/New_York,EDT,-14400000,1.58,,,0.125,0.0141,0.0276,0.0349,146.55k,149.58k,60.46M,,65.73M,0.05%,0.00%,,,,,,,,,,,0.00%,"Dec 19, 2019",,1:1000,"Dec 19, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,"-2,396.36%",-67.48%,,116.48k,0.00,-32.10%,100.43k,-2.14M,-7.08M,-0.3390,,8.54k,0,6.66M,,0.00,-0.31,-715.41k,2.47M,Value,91367,Healthcare,"Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its electrocuetical medical devices are also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post- concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.",Woodland Hills,800 489 4774,CA,1609372800,United States,http://www.endonovo.com,86400,6320 Canoga Avenue,818 230 9899,Biotechnology,15th Floor
